CFG
MYGN icon

Citizens Financial Group’s Myriad Genetics MYGN Stock Holding History

Citizens Financial Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-542
Closed -$19K – 505
2017
Q4 		$19K Hold
542
– – ﹤0.01% 385
2017
Q3 		$20K Hold
542
– – ﹤0.01% 382
2017
Q2 		$14K Buy
+542
New +$11.5K ﹤0.01% 393

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citizens Financial Group's MYGN Position: Q1 2018 in Review

Citizens Financial Group sold out of Myriad Genetics (MYGN) in Q1 2018, closing a stake of 542 shares — an estimated $19K sold.

Citizens Financial Group first reported a position in MYGN in Q2 2017 and held it in 3 quarters. The position peaked at $20K in Q3 2017. 260 funds tracked by Wall St. Rank hold MYGN as of Q1 2018.

  • Citizens Financial Group reported no remaining Myriad Genetics position as of Q1 2018 after selling out during the quarter.
  • Citizens Financial Group sold 542 Myriad Genetics shares in Q1 2018, an estimated $19K.
  • Citizens Financial Group first reported a position in Myriad Genetics in Q2 2017 and held it in 3 quarters.
  • Citizens Financial Group's Myriad Genetics position peaked at $20K in Q3 2017.
  • 260 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2018.

Based on Citizens Financial Group's 13F filing for Q1 2018, filed 11 May 2018.